Stamford, CT -- (SBWIRE) -- 09/03/2013 -- High Rising Stocks provides investors with the hot penny stock alerts on a regular basis. We will send you alerts through our Free E Newsletters with High Yielding alerts, market forecasting, stock tips and strategies, and offer you the tools to help you along the way with the goal of keeping you loyal to our service. Today’s stocks to watch are: Nokia Corporation (ADR)(NYSE:NOK), Alcatel Lucent SA (ADR) (NYSE:ALU), Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Nokia Corporation (ADR)(NYSE:NOK) shares soared 37.31% to $5.36. Microsoft Corporation (NASDAQ:MSFT) on Sept. 3 announced its agreement to acquire Nokia Corporation (ADR) (NYSE:NOK)’s Devices and Services section, including the right to license the patent and to use the mapping services, for €5.44 billion. Under the terms of the agreement, the software giant will also acquire the mobile phone and smartphone business units including the Lumia & Asha brands and related production facilities of the Finnish smartphone manufacturer.
Is NOK A Strong At The CMP? Get Advantage Of Our Free Trend Analysis Here
Alcatel Lucent SA (ADR) (NYSE:ALU) shares climbed 11.63% to $2.88. The company on August 28 announced that it has appointed Jean Raby as its new finance chief, as the telecommunications-equipment maker continues its turnaround under the leadership of its new chief executive. Mr. Raby, 49, a former partner and managing director at Goldman Sachs Group Inc.'s investment bank division, will become chief financial and legal officer as of Sept. 1, replacing Chief Financial Officer Paul Tufano, the company said.
Is ALU A Good Buy After The Recent Price Movement? Find Out Here
Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares climbed 4.21% to $8.66. The company, on Sept. 2, announced that the European Commission has granted Roche European Union (EU) marketing authorization for the use of a time-saving subcutaneous (SC) formulation of Herceptin(R) (trastuzumab) for the treatment of HER2-positive breast cancer. This formulation utilizes Halozyme's recombinant human hyaluronidase (rHuPH20) and is administered in two to five minutes, rather than 30 to 90 minutes with the standard intravenous form.
Should Investors Rush To Buy HALO After The Solid Rally? Get Special Report Here
High Rising Stocksis always searching the market every day for massive penny stock runs before they happen so you don't have to.We will send you alerts through our Free E Newsletters with High Yielding alerts, market forecasting, stock tips and strategies, and offer you the tools to help you along the way with the goal of keeping you loyal to our service.
Carriage Consulting Group, High Rising Stocks, their Members, officers, directors, employees, affiliates, or any other related person(s) (collectively, “High Rising Stocks”) are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. High Rising Stocks as defined are neither licensed nor qualified to provide investment advice and you are specifically and adamantly advised not to rely upon anything said/posted/communicated/implied or expressed by High Rising Stocks as defined.
Read full Disclaimer at: http://highrisingstocks.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)